SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

NCT05586581 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

HIV Associated Neurocognitive Disorder
HIV Dementia
HIV Encephalitis
Healthy

Interventions

DRUG: SV2A PET
DRUG: TSPO PET

Sponsor

Yale University

Collaborators

[object Object]
[object Object]